| Year |
Citation |
Score |
| 2023 |
Rashidi A, Billingham LK, Zolp A, Chia TY, Silvers C, Katz JL, Park CH, Delay S, Boland L, Geng Y, Markwell SM, Dmello C, Arrieta VA, Zilinger K, Jacob IM, ... ... Lesniak MS, et al. Myeloid cell-derived creatine in the hypoxic niche promotes glioblastoma growth. Cell Metabolism. PMID 38134929 DOI: 10.1016/j.cmet.2023.11.013 |
0.307 |
|
| 2023 |
Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P, Miska J, Yeeravalli R, Habashy K, Saganty R, Kang SJ, ... ... Lesniak MS, et al. Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nature Communications. 14: 1566. PMID 36949040 DOI: 10.1038/s41467-023-36878-2 |
0.306 |
|
| 2023 |
Ellingwood A, Wan H, Lee-Chang C, Lesniak MS, Zhang P. Therapeutic Nanoparticles Harness Myeloid Cells for Brain Tumor-targeted Delivery and Immunomodulation. Material Matters : Chemistry Driving Performance. 17: 29-36. PMID 36789150 |
0.301 |
|
| 2023 |
Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM, Lee-Chang C, Miska J, Lesniak MS, Gottschalk S, Balyasnikova IV. IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. Journal For Immunotherapy of Cancer. 11. PMID 36759014 DOI: 10.1136/jitc-2022-006239 |
0.309 |
|
| 2023 |
Khan F, Pang L, Dunterman M, Lesniak MS, Heimberger AB, Chen P. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. The Journal of Clinical Investigation. 133. PMID 36594466 DOI: 10.1172/JCI163446 |
0.344 |
|
| 2022 |
Wei J, Song R, Sabbagh A, Marisetty A, Shukla N, Fang D, Najem H, Ott M, Long J, Zhai L, Lesniak MS, James CD, Platanias L, Curran M, Heimberger AB. Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system. Oncoimmunology. 11: 2062827. PMID 35433114 DOI: 10.1080/2162402X.2022.2062827 |
0.333 |
|
| 2022 |
Xuan W, Hsu WH, Khan F, Dunterman M, Pang L, Wainwright DA, Ahmed AU, Heimberger AB, Lesniak MS, Chen P. Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunology Research. PMID 35413115 DOI: 10.1158/2326-6066.CIR-21-0559 |
0.319 |
|
| 2022 |
Petrosyan E, Fares J, Cordero A, Rashidi A, Arrieta VA, Kanojia D, Lesniak MS. Repurposing Autophagy Regulators in Brain Tumors. International Journal of Cancer. PMID 35179776 DOI: 10.1002/ijc.33965 |
0.331 |
|
| 2022 |
Cordero A, Ramsey MD, Kanojia D, Fares J, Petrosyan E, Schwartz CW, Burga R, Zhang P, Rashidi A, Castro B, Xiao T, Lee-Chang C, Miska J, Balyasnikova IV, Ahmed AU, ... Lesniak MS, et al. Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer. Proceedings of the National Academy of Sciences of the United States of America. 119. PMID 34969858 DOI: 10.1073/pnas.2112491119 |
0.314 |
|
| 2021 |
Xuan W, Lesniak MS, James CD, Heimberger AB, Chen P. Context-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms. Trends in Immunology. PMID 33663953 DOI: 10.1016/j.it.2021.02.004 |
0.355 |
|
| 2021 |
Pituch KC, Zannikou M, Ilut L, Xiao T, Chastkofsky M, Sukhanova M, Bertolino N, Procissi D, Amidei C, Horbinski CM, Aboody KS, James CD, Lesniak MS, Balyasnikova IV. Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33627401 DOI: 10.1073/pnas.2015800118 |
0.369 |
|
| 2021 |
Fares J, Cordero A, Kanojia D, Lesniak MS. The Network of Cytokines in Brain Metastases. Cancers. 13. PMID 33466236 DOI: 10.3390/cancers13010142 |
0.32 |
|
| 2021 |
Lee-Chang C, Miska J, Hou D, Rashidi A, Zhang P, Burga RA, Jusué-Torres I, Xiao T, Arrieta VA, Zhang DY, Lopez-Rosas A, Han Y, Sonabend AM, Horbinski CM, Stupp R, ... ... Lesniak MS, et al. Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma. The Journal of Experimental Medicine. 218. PMID 32991668 DOI: 10.1084/jem.20200913 |
0.301 |
|
| 2020 |
Chastkofsky MI, Pituch KC, Katagi H, Zannikou M, Ilut L, Xiao T, Han Y, Sonabend AM, Curiel DT, Bonner ER, Nazarian J, Horbinski C, James CD, Saratsis AM, Hashizume R, ... Lesniak MS, et al. Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33272983 DOI: 10.1158/1078-0432.CCR-20-1499 |
0.324 |
|
| 2020 |
Kanojia D, Panek WK, Cordero A, Fares J, Xiao A, Savchuk S, Kumar K, Xiao T, Pituch KC, Miska J, Zhang P, Kam KL, Horbinski C, Balyasnikova IV, Ahmed AU, ... Lesniak MS, et al. BET inhibition increases βIII-tubulin expression and sensitizes metastatic breast cancer in the brain to vinorelbine. Science Translational Medicine. 12. PMID 32848091 DOI: 10.1126/Scitranslmed.Aax2879 |
0.365 |
|
| 2020 |
Wu J, Ning P, Gao R, Feng Q, Shen Y, Zhang Y, Li Y, Xu C, Qin Y, Plaza GR, Bai Q, Fan X, Li Z, Han Y, Lesniak MS, et al. Programmable ROS-Mediated Cancer Therapy via Magneto-Inductions. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 7: 1902933. PMID 32596106 DOI: 10.1002/Advs.201902933 |
0.313 |
|
| 2020 |
Mooney R, Majid AA, Batalla-Covello J, Machado D, Liu X, Gonzaga J, Tirughana R, Hammad M, Dellinger TH, Lesniak MS, Curiel DT, Aboody KS. Erratum: Enhanced Delivery of Oncolytic Adenovirus by Neural Stem Cells for Treatment of Metastatic Ovarian Cancer. Molecular Therapy Oncolytics. 17: 508. PMID 32577499 DOI: 10.1016/J.Omto.2020.05.005 |
0.362 |
|
| 2020 |
Kane JR, Zhao J, Tsujiuchi T, Laffleur B, Arrieta VA, Mahajan A, Rao G, Mela A, Dmello C, Chen L, Zhang DY, Gonzalez-Buendia E, Lee-Chang C, Xiao T, Rothschild G, ... ... Lesniak MS, et al. CD8 T-cell-mediated immunoediting influences genomic evolution and immune evasion in murine gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32430477 DOI: 10.1158/1078-0432.Ccr-19-3104 |
0.409 |
|
| 2020 |
Fares J, Kanojia D, Rashidi A, Ulasov I, Lesniak MS. Genes that Mediate Metastasis across the Blood-Brain Barrier. Trends in Cancer. PMID 32417182 DOI: 10.1016/J.Trecan.2020.04.007 |
0.399 |
|
| 2020 |
Ulasov I, Borovjagin A, Fares J, Yakushov S, Malin D, Timashev P, Lesniak MS. MicroRNA 345 (miR345) regulates KISS1-E-cadherin functional interaction in breast cancer brain metastases. Cancer Letters. PMID 32246957 DOI: 10.1016/J.Canlet.2020.03.025 |
0.352 |
|
| 2020 |
Fares J, Kanojia D, Rashidi A, Ulasov I, Lesniak MS. Landscape of Combination Therapy Trials in Breast Cancer Brain Metastasis. International Journal of Cancer. PMID 32086955 DOI: 10.1002/Ijc.32937 |
0.315 |
|
| 2019 |
Chen M, Wu J, Ning P, Wang J, Ma Z, Huang L, Plaza GR, Shen Y, Xu C, Han Y, Lesniak MS, Liu Z, Cheng Y. Remote Control of Mechanical Forces via Mitochondrial-Targeted Magnetic Nanospinners for Efficient Cancer Treatment. Small (Weinheim An Der Bergstrasse, Germany). e1905424. PMID 31867877 DOI: 10.1002/Smll.201905424 |
0.379 |
|
| 2019 |
Rashidi A, Miska J, Lee-Chang C, Kanojia D, Panek WK, Lopez-Rosas A, Zhang P, Han Y, Xiao T, Pituch KC, Kim JW, Talebian M, Fares J, Lesniak MS. GCN2 is essential for CD8 T cell survival and function in murine models of malignant glioma. Cancer Immunology, Immunotherapy : Cii. PMID 31844909 DOI: 10.1007/S00262-019-02441-6 |
0.367 |
|
| 2019 |
Ulasov I, Fares J, Timashev P, Lesniak MS. Editing Cytoprotective Autophagy in Glioma: An Unfulfilled Potential for Therapy. Trends in Molecular Medicine. PMID 31787452 DOI: 10.1016/J.Molmed.2019.11.001 |
0.411 |
|
| 2019 |
Zhang P, Miska J, Lee-Chang C, Rashidi A, Panek WK, An S, Zannikou M, Lopez-Rosas A, Han Y, Xiao T, Pituch KC, Kanojia D, Balyasnikova IV, Lesniak MS. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 31712430 DOI: 10.1073/Pnas.1906346116 |
0.377 |
|
| 2019 |
Fares J, Kanojia D, Cordero A, Rashidi A, Miska J, Schwartz CW, Savchuk S, Ahmed AU, Balyasnikova IV, Cristofanilli M, Gradishar WJ, Lesniak MS. Current state of clinical trials in breast cancer brain metastases. Neuro-Oncology Practice. 6: 392-401. PMID 31555454 DOI: 10.1093/Nop/Npz003 |
0.319 |
|
| 2019 |
Lee-Chang C, Rashidi A, Miska J, Zhang P, Pituch KC, Hou D, Xiao T, Fischietti M, Kang SJ, Appin CL, Horbinski C, Platanias LC, Lopez-Rosas A, Han Y, Balyasnikova IV, ... Lesniak MS, et al. Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma. Cancer Immunology Research. PMID 31530559 DOI: 10.1158/2326-6066.Cir-19-0240 |
0.382 |
|
| 2019 |
Ulasov IV, Mijanovic O, Savchuk S, Gonzalez-Buendia E, Sonabend A, Xiao T, Timashev P, Lesniak MS. TMZ regulates GBM stemness via MMP14-DLL4-Notch3 pathway. International Journal of Cancer. PMID 31443114 DOI: 10.1002/Ijc.32636 |
0.332 |
|
| 2019 |
Cordero A, Kanojia D, Miska J, Panek WK, Xiao A, Han Y, Bonamici N, Zhou W, Xiao T, Wu M, Ahmed AU, Lesniak MS. FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis. Oncogene. PMID 31324889 DOI: 10.1038/S41388-019-0893-4 |
0.339 |
|
| 2019 |
Spencer D, Yu D, Morshed RA, Li G, Pituch KC, Gao DX, Bertolino N, Procissi D, Lesniak MS, Balyasnikova IV. Pharmacologic modulation of nasal epithelium augments neural stem cell targeting of glioblastoma. Theranostics. 9: 2071-2083. PMID 31037157 DOI: 10.7150/Thno.29581 |
0.479 |
|
| 2019 |
Hasse A, Dapash M, Jeong Y, Ansari SA, Carroll TJ, Lesniak M, Ginat DT. Correlation of post-contrast T1-weighted MRI surface regularity, tumor bulk, and necrotic volume with Ki67 and p53 in glioblastomas. Neuroradiology. PMID 31020343 DOI: 10.1007/S00234-019-02204-1 |
0.313 |
|
| 2019 |
Miska J, Lee-Chang C, Rashidi A, Muroski ME, Chang AL, Lopez-Rosas A, Zhang P, Panek WK, Cordero A, Han Y, Ahmed AU, Chandel NS, Lesniak MS. HIF-1α Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma. Cell Reports. 27: 226-237.e4. PMID 30943404 DOI: 10.1016/J.Celrep.2019.03.029 |
0.33 |
|
| 2019 |
Hasan T, Caragher SP, Shireman JM, Park CH, Atashi F, Baisiwala S, Lee G, Guo D, Wang JY, Dey M, Wu M, Lesniak MS, Horbinski CM, James CD, Ahmed AU. Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma. Cell Death & Disease. 10: 292. PMID 30926789 DOI: 10.1038/S41419-019-1387-6 |
0.384 |
|
| 2019 |
Mijanović O, Branković A, Panin AN, Savchuk S, Timashev P, Ulasov I, Lesniak MS. Cathepsin B: A sellsword of cancer progression. Cancer Letters. 449: 207-214. PMID 30796968 DOI: 10.1016/J.Canlet.2019.02.035 |
0.325 |
|
| 2019 |
Mooney R, Majid AA, Batalla-Covello J, Machado D, Liu X, Gonzaga J, Tirughana R, Hammad M, Lesniak MS, Curiel DT, Aboody KS. Enhanced Delivery of Oncolytic Adenovirus by Neural Stem Cells for Treatment of Metastatic Ovarian Cancer. Molecular Therapy Oncolytics. 12: 79-92. PMID 30719498 DOI: 10.1016/J.Omto.2018.12.003 |
0.459 |
|
| 2019 |
Caragher SP, Shireman JM, Huang M, Miska J, Atashi F, Baisiwala S, Hong Park C, Saathoff MR, Warnke L, Xiao T, Lesniak MS, James CD, Meltzer H, Tryba AK, Ahmed AU. Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 30651332 DOI: 10.1523/Jneurosci.1589-18.2018 |
0.407 |
|
| 2019 |
An S, Rooney MK, Miska J, Lee Chang C, Zhang P, Han Y, Lopez-Rosas A, Lesniak MS, Sachdev S. RDNA-05. RADIOTHERAPY PROMOTES ONCOPROGRESSIVE CROSSTALK BETWEEN GLIOBLASTOMA TUMOR CELLS AND M2 MACROPHAGES VIA THE NLRP3 INFLAMMASOME PATHWAY Neuro-Oncology. 21: vi207-vi208. DOI: 10.1093/Neuonc/Noz175.865 |
0.433 |
|
| 2019 |
Miska J, Lee Chang C, Rashidi A, Han Y, Lopez-Rosas A, Lesniak MS. IMMU-43. POLYAMINE METABOLISM REGULATES MYELOID IMMUNE SUPPRESSION IN GLIOBLASTOMA Neuro-Oncology. 21: vi128-vi128. DOI: 10.1093/Neuonc/Noz175.535 |
0.411 |
|
| 2019 |
Robert Kane J, Zhao J, Tsujiuchi T, Laffleur B, Mahajan A, Rao G, Mela A, Dmello C, Arrieta VA, Chen L, Zhang DY, Lee-Chang C, Xiao T, Rothschild G, Basu U, ... ... Lesniak MS, et al. IMMU-42. CD8+ T-CELLS MEDIATE IMMUNOEDITING, AND INFLUENCE GENOTYPE, TUMOR ONCOGENIC PATHWAYS AND MICROENVIRONMENT DURING PROGRESSION OF MURINE GLIOMAS Neuro-Oncology. 21: vi128-vi128. DOI: 10.1093/Neuonc/Noz175.534 |
0.415 |
|
| 2019 |
Zhang P, Zannikou M, Lesniak MS, Balyasnikova I. EXTH-68. INTRANASAL DELIVERY OF DRUG-LOADED LIPOSOMES SENSITIZES TUMORS TO IRRADIATION IN SYNGENEIC MODEL OF GLIOMA. Neuro-Oncology. 21: vi96-vi96. DOI: 10.1093/Neuonc/Noz175.398 |
0.393 |
|
| 2019 |
Idbaih A, Ducray F, DeGroot J, Stupp R, Guyotat J, Lesniak MS, Sonabend A, Weinberg J, Desseaux C, Canney M, Schmitt C, Carpentier A. ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN Neuro-Oncology. 21: vi26-vi27. DOI: 10.1093/Neuonc/Noz175.099 |
0.33 |
|
| 2018 |
Wu C, Muroski ME, Miska J, Lee-Chang C, Shen Y, Rashidi A, Zhang P, Xiao T, Han Y, Lopez-Rosas A, Cheng Y, Lesniak MS. Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 30553919 DOI: 10.1016/J.Nano.2018.11.015 |
0.419 |
|
| 2018 |
Panek WK, Pituch KC, Miska J, Kim JW, Rashidi A, Kanojia D, Lopez-Rosas A, Han Y, Yu D, Chang CL, Kane JR, Zhang P, Cordero A, Lesniak MS. Local Application of Autologous Platelet-Rich Fibrin Patch (PRF-P) Suppresses Regulatory T Cell Recruitment in a Murine Glioma Model. Molecular Neurobiology. PMID 30460615 DOI: 10.1007/S12035-018-1430-0 |
0.395 |
|
| 2018 |
Lukas RV, Juhász C, Wainwright DA, James CD, Kennedy E, Stupp R, Lesniak MS. Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod. Journal of Neuro-Oncology. PMID 30415456 DOI: 10.1007/S11060-018-03013-X |
0.386 |
|
| 2018 |
Xu C, Feng Q, Yang H, Wang G, Huang L, Bai Q, Zhang C, Wang Y, Chen Y, Cheng Q, Chen M, Han Y, Yu Z, Lesniak MS, Cheng Y. A Light-Triggered Mesenchymal Stem Cell Delivery System for Photoacoustic Imaging and Chemo-Photothermal Therapy of Triple Negative Breast Cancer. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 5: 1800382. PMID 30356957 DOI: 10.1002/Advs.201800382 |
0.406 |
|
| 2018 |
Kim JW, Kane JR, Panek WK, Young JS, Rashidi A, Yu D, Kanojia D, Hasan T, Miska J, Gómez-Lim MA, Ulasov IV, Balyasnikova IV, Ahmed AU, Wainwright DA, Lesniak MS. A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 30027430 DOI: 10.1007/S13311-018-0650-3 |
0.37 |
|
| 2018 |
Kaverina NV, Kadagidze ZG, Borovjagin AV, Karseladze AI, Kim CK, Lesniak MS, Miska J, Zhang P, Baryshnikova MA, Xiao T, Ornelles D, Cobbs C, Khramtsov A, Ulasov IV. Tamoxifen overrides autophagy inhibition in Beclin-1-deficient glioma cells and their resistance to adenovirus-mediated oncolysis via upregulation of PUMA and BAX. Oncogene. PMID 29991800 DOI: 10.1038/S41388-018-0395-9 |
0.403 |
|
| 2018 |
Kim JW, Chang AL, Kane JR, Young JS, Qiao J, Lesniak MS. Gene Therapy and Virotherapy of Gliomas. Progress in Neurological Surgery. 32: 112-123. PMID 29990979 DOI: 10.1159/000469685 |
0.4 |
|
| 2018 |
Javier R, Shaikh N, Lesniak MS, Sonabend A, Stupp R, Behdad A, Horbinski C. B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma. Diagnostic Pathology. 13: 37. PMID 29871654 DOI: 10.1186/S13000-018-0717-9 |
0.317 |
|
| 2018 |
Ulasov IV, Lenz G, Lesniak MS. Autophagy in glioma cells: an identity crisis with a clinical perspective. Cancer Letters. PMID 29709703 DOI: 10.1016/J.Canlet.2018.04.034 |
0.389 |
|
| 2018 |
Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Han Y, Lesniak MS, Gottschalk S, Balyasnikova IV. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29503195 DOI: 10.1016/J.Ymthe.2018.02.001 |
0.375 |
|
| 2018 |
Chang CL, Miska J, Rashidi A, Zhang P, Appin C, Xiao T, Lopez-Rosas A, Han Y, Lesniak M. IMMU-11. IDENTIFICATION OF GLIOMA-ASSOCIATED REGULATORY B CELLS AND EFFECTS OF RITUXIMAB IMMUNOTHERAPY Neuro-Oncology. 20: vi123-vi123. DOI: 10.1093/Neuonc/Noy148.514 |
0.331 |
|
| 2018 |
Pituch K, Zannikou M, Ilut L, Chen C, Lesniak M, Gottschalk S, Krenciute G, Balyasnikova I. EXTH-32. TRANSGENIC EXPRESSION OF IL15 IMPROVES THE EFFICACY OF CAR T CELLS IN AN IMMUNE COMPETENT GLIOBLASTOMA MODEL Neuro-Oncology. 20: vi92-vi92. DOI: 10.1093/Neuonc/Noy148.381 |
0.332 |
|
| 2017 |
Platonov ME, Borovjagin AV, Kaverina N, Xiao T, Kadagidze Z, Lesniak M, Baryshnikova M, Ulasov IV. KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro. Cancer Letters. PMID 29269086 DOI: 10.1016/J.Canlet.2017.12.024 |
0.395 |
|
| 2017 |
Panek WK, Kane JR, Young JS, Rashidi A, Kim JW, Kanojia D, Lesniak MS. Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma. Oncotarget. 8: 89391-89405. PMID 29179527 DOI: 10.18632/Oncotarget.20810 |
0.45 |
|
| 2017 |
Panek WK, Khan OF, Yu D, Lesniak MS. Multiplexed nanomedicine for brain tumors: nanosized Hercules to tame our Lernaean Hydra inside? Nanomedicine (London, England). PMID 28971724 DOI: 10.2217/Nnm-2017-0260 |
0.384 |
|
| 2017 |
Li G, Bonamici N, Dey M, Lesniak MS, Balyasnikova IV. Intranasal Delivery of Stem Cell-based Therapies for the Treatment of Brain Malignancies. Expert Opinion On Drug Delivery. PMID 28895435 DOI: 10.1080/17425247.2018.1378642 |
0.457 |
|
| 2017 |
Muroski ME, Miska J, Chang AL, Zhang P, Rashidi A, Moore H, Lopez-Rosas A, Han Y, Lesniak MS. Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate. Scientific Reports. 7: 5790. PMID 28724939 DOI: 10.1038/S41598-017-05556-X |
0.345 |
|
| 2017 |
Yu D, Khan OF, Suvà ML, Dong B, Panek WK, Xiao T, Wu M, Han Y, Ahmed AU, Balyasnikova IV, Zhang HF, Sun C, Langer R, Anderson DG, Lesniak MS. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proceedings of the National Academy of Sciences of the United States of America. PMID 28696296 DOI: 10.1073/Pnas.1701911114 |
0.452 |
|
| 2017 |
Feng Q, Shen Y, Fu Y, Muroski ME, Zhang P, Wang Q, Xu C, Lesniak MS, Li G, Cheng Y. Self-Assembly of Gold Nanoparticles Shows Microenvironment-Mediated Dynamic Switching and Enhanced Brain Tumor Targeting. Theranostics. 7: 1875-1889. PMID 28638474 DOI: 10.7150/Thno.18985 |
0.385 |
|
| 2017 |
Yu D, Li G, Lesniak MS, Balyasnikova IV. Intranasal Delivery of Therapeutic Stem Cells to Glioblastoma in a Mouse Model. Journal of Visualized Experiments : Jove. PMID 28605391 DOI: 10.3791/55845 |
0.464 |
|
| 2017 |
Kim JW, Miska J, Young JS, Rashidi A, Kane JR, Panek WK, Kanojia D, Han Y, Balyasnikova IV, Lesniak MS. A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model. Molecular Therapy Oncolytics. 5: 97-104. PMID 28573184 DOI: 10.1016/J.Omto.2017.05.001 |
0.406 |
|
| 2017 |
Shen Y, Wu C, Uyeda TQP, Plaza GR, Liu B, Han Y, Lesniak MS, Cheng Y. Elongated Nanoparticle Aggregates in Cancer Cells for Mechanical Destruction with Low Frequency Rotating Magnetic Field. Theranostics. 7: 1735-1748. PMID 28529648 DOI: 10.7150/Thno.18352 |
0.314 |
|
| 2017 |
Rincón E, Cejalvo T, Kanojia D, Alfranca A, Rodríguez-Milla MÁ, Hoyos RAG, Han Y, Zhang L, Alemany R, Lesniak MS, García-Castro J. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. Oncotarget. PMID 28525366 DOI: 10.18632/Oncotarget.17557 |
0.481 |
|
| 2017 |
Yu D, Kim JW, Kanojia D, Han Y, Mathis JM, Chen C, Aboody K, Lesniak MS, Balyasnikova I. STEM-37. GENETIC EDITING OF NEURAL STEM CELLS FOR INTRANASAL THERAPEUTIC DELIVERY TO MALIGNANT BRAIN TUMORS Neuro-Oncology. 19: vi233-vi233. DOI: 10.1093/Neuonc/Nox168.951 |
0.432 |
|
| 2017 |
Wu M, Xiao T, Miska J, Kane JR, Kanojia D, Li X, Lesniak MS. PATH-22. BRAINGENEEXPRESS: A WEB APPLICATION FOR DATA VISUALIZATION OF BRAIN TUMOR RESEARCH Neuro-Oncology. 19: vi175-vi175. DOI: 10.1093/Neuonc/Nox168.713 |
0.332 |
|
| 2017 |
Miska J, Muroski M, Rashidi A, Chang A, Zhang P, Han Y, Lesniak MS. IMMU-37. METABOLIC REPROGRAMMING OF THE GLIOMA MICROENVIRONMENT INHIBITS TUMOR IMMUNOSUPPRESSION Neuro-Oncology. 19: vi120-vi120. DOI: 10.1093/Neuonc/Nox168.495 |
0.356 |
|
| 2017 |
Panek WK, Kanojia D, Xiao A, Lesniak MS. EXTH-16. RATIONAL DESIGN OF COMBINATION THERAPY AGAINST HER2+ BRAIN METASTASES OF BREAST CANCER USING JQ-1 AND VINORELBINE Neuro-Oncology. 19: vi76-vi76. DOI: 10.1093/Neuonc/Nox168.311 |
0.303 |
|
| 2017 |
Park C, Atashi F, Caragher S, Baisiwala S, Lesniak MS, James CD, Ahmed A. DRES-18. EZH2/PRC2-MEDIATED EPIGENETIC PLASTICITY PROMOTES THERAPEUTIC RESISTANCE BY REGULATING STAT3 ACTIVATION GENE NETWORK IN THE GLIOMA STEM CELLS Neuro-Oncology. 19: vi67-vi68. DOI: 10.1093/Neuonc/Nox168.276 |
0.333 |
|
| 2017 |
Kanojia D, Panek WK, Cordero A, Xiao A, Miska J, Wu M, Kim JW, Zhou W, Ahmed A, Lesniak MS. CBIO-29. ACOT7 REGULATES COLONIZATION OF BREAST CANCER CELLS IN THE BRAIN BY REGULATING ENDOPLASMIC RETICULUM STRESS RESPONSE Neuro-Oncology. 19: vi38-vi38. DOI: 10.1093/Neuonc/Nox168.147 |
0.304 |
|
| 2017 |
Lesniak MS, Stupp R, Sachdev S, Lukas R, Chandler J, Portnow J, Amidei C, Miska J, Balyasnikova I, Ahmed A, Curiel D, Strong T, LeFever A, Adams A, Giles F, et al. ACTR-36. A PHASE I STUDY OF NEURAL STEM CELLS LOADED WITH AN ONCOLYTIC ADENOVIRUS FOR PATIENTS WITH NEWLY DIAGNOSED MALIGNANT GLIOMA: PRELIMINARY SAFETY AND DATA ANALYSIS Neuro-Oncology. 19: vi8-vi8. DOI: 10.1093/Neuonc/Nox168.027 |
0.46 |
|
| 2017 |
Chastkofsky M, Procissi D, Yang C, Goldman S, Lesniak M, Hashizume R, Balyasnikova I. DIPG-19. MESENCHYMAL STEM CELLS TARGET DIFFUSE INTRINSIC PONTINE GLIOMA IN MICE AFTER INTRANASAL DELIVERY Neuro-Oncology. 19: iv8-iv8. DOI: 10.1093/Neuonc/Nox083.034 |
0.361 |
|
| 2017 |
Chastkofsky MI, Procissi D, Yang C, Goldman S, Lesniak MS, Hashizume R, Balyasnikova IV. P11.01 Intranasal delivery of mesenchymal stem cells targets diffuse intrinsic pontine glioma in mouse model Neuro-Oncology. 19: iii91-iii91. DOI: 10.1093/Neuonc/Nox036.346 |
0.362 |
|
| 2017 |
Panek WK, Kim JW, Pituch KC, Kane JR, Kanojia D, Cordero A, Miska J, Rashidi A, Young JS, Lesniak MS. P08.46 Synergistic Therapeutic Efficacy via Immunomodulatory Platelet Rich Fibrin Patch (PRF-P) in Combination with Oncolytic Adenovirus for the Treatment of Glioma Neuro-Oncology. 19: iii64-iii64. DOI: 10.1093/Neuonc/Nox036.235 |
0.417 |
|
| 2017 |
Ahmed AU, Horbinski CM, Stupp R, Lesniak MS, James CD. P08.01 Tumor cell subpopulation changes during intracranial glioblastoma patient derived xenograft recurrence following radiation, temozolomide, or combination therapy Neuro-Oncology. 19: iii53-iii53. DOI: 10.1093/Neuonc/Nox036.191 |
0.39 |
|
| 2017 |
Yu D, Khan OF, Suvà ML, Panek WK, Wu M, Han Y, Ahmed AU, Balyasnikova IV, Anderson DG, Langer R, Lesniak MS. OS06.2 Combination RNAi therapy against glioma stem cells via sustained lipopolymeric nanoparticle delivery delays tumor progression Neuro-Oncology. 19: iii11-iii11. DOI: 10.1093/Neuonc/Nox036.036 |
0.309 |
|
| 2016 |
Spencer DA, Auffinger BM, Murphy JP, Muroski ME, Qiao J, Govind Y, Lesniak MS. Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy. Current Cancer Drug Targets. PMID 27993114 DOI: 10.2174/1568009616666161215161924 |
0.473 |
|
| 2016 |
Lee G, Auffinger B, Guo D, Hasan T, Deheeger M, Tobias AL, Kim JY, Atashi F, Zhang L, Lesniak MS, David JC, Ahmed AU. De-differentiation of glioma cells to glioma stem-like cells by therapeutic stress-induced HIF signaling in the recurrent GBM model. Molecular Cancer Therapeutics. PMID 27765847 DOI: 10.1158/1535-7163.MCT-15-0675 |
0.341 |
|
| 2016 |
Miska J, Rashidi A, Chang AL, Muroski ME, Han Y, Zhang L, Lesniak MS. Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunology, Immunotherapy : Cii. PMID 27734112 DOI: 10.1007/S00262-016-1912-8 |
0.438 |
|
| 2016 |
Dey M, Yu D, Kanojia D, Li G, Sukhanova M, Spencer DA, Pituch KC, Zhang L, Han Y, Ahmed AU, Aboody KS, Lesniak MS, Balyasnikova IV. Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma. Stem Cell Reports. PMID 27594591 DOI: 10.1016/J.Stemcr.2016.07.024 |
0.487 |
|
| 2016 |
Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, Han Y, Wu M, Zhang L, Horbinski C, Ahmed AU, ... Lesniak MS, et al. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Research. PMID 27530322 DOI: 10.1158/0008-5472.Can-16-0144 |
0.428 |
|
| 2016 |
Roth S, Dreixler JC, Mathew B, Balyasnikova I, Mann JR, Boddapoti V, Xue L, Lesniak MS. Hypoxic-Preconditioned Bone Marrow Stem Cell Medium Significantly Improves Outcome After Retinal Ischemia in Rats. Investigative Ophthalmology & Visual Science. 57: 3522-3532. PMID 27367588 DOI: 10.1167/Iovs.15-17381 |
0.303 |
|
| 2016 |
Kim JW, Auffinger B, Spencer DA, Miska J, Chang AL, Kane JR, Young JS, Kanojia D, Qiao J, Mann JF, Zhang L, Wu M, Ahmed AU, Aboody KS, Strong TV, ... ... Lesniak MS, et al. Single dose GLP toxicity and biodistribution study of a conditionally replicative adenovirus vector, CRAd-S-pk7, administered by intracerebral injection to Syrian hamsters. Journal of Translational Medicine. 14: 134. PMID 27184224 DOI: 10.1186/S12967-016-0895-8 |
0.354 |
|
| 2016 |
Morshed RA, Muroski ME, Dai Q, Wegscheid ML, Auffinger B, Yu D, Han Y, Zhang L, Wu M, Cheng Y, Lesniak MS. Cell penetrating peptide-modified gold nanoparticles for the delivery of doxorubicin to brain metastatic breast cancer. Molecular Pharmaceutics. PMID 27169484 DOI: 10.1021/Acs.Molpharmaceut.6B00004 |
0.37 |
|
| 2016 |
Muroski ME, Morshed RA, Cheng Y, Vemulkar T, Mansell R, Han Y, Zhang L, Aboody KS, Cowburn RP, Lesniak MS. Controlled Payload Release by Magnetic Field Triggered Neural Stem Cell Destruction for Malignant Glioma Treatment. Plos One. 11: e0145129. PMID 26734932 DOI: 10.1371/Journal.Pone.0145129 |
0.39 |
|
| 2016 |
Kim JW, Morshed RA, Kane JR, Auffinger B, Qiao J, Lesniak MS. Viral Vector Production: Adenovirus. Methods in Molecular Biology (Clifton, N.J.). 1382: 115-30. PMID 26611583 DOI: 10.1007/978-1-4939-3271-9_9 |
0.339 |
|
| 2016 |
Krishnan V, Mitchell K, Miska J, George S, Shaw P, Seewaldt V, Lesniak M, Chekmareva M, Becker L, Parkash V, Miranti C, Rinker-Schaeffer C. Abstract A82: Ovarian cancer cells hijack immune functions of omental milky spots for metastatic colonization. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A82 |
0.361 |
|
| 2016 |
Kumthekar P, Ahmed A, Lesniak M, James CD, Horbinski C. TMOD-26. DEVELOPING PATIENT-DERIVED XENOGRAFT MODELS OF METASTATIC CANCER TO THE BRAIN Neuro-Oncology. 18: vi212-vi212. DOI: 10.1093/Neuonc/Now212.896 |
0.321 |
|
| 2016 |
Auffinger B, Hasan T, Lee G, Tobias A, Deheeger M, Han Y, Guo D, Lesniak M, James CD, Ahmed A. TMIC-24. THE CONTRIBUTION OF VASCULAR CO-OPTION AND TUMOR-DERIVED ENDOTHELIAL CELLS TO GBM RECURRENCE Neuro-Oncology. 18: vi205-vi205. DOI: 10.1093/Neuonc/Now212.864 |
0.35 |
|
| 2016 |
Yu D, Bonamici N, Tsai H, Cheng S, Wu M, Pituch K, Han Y, Chen C, Lesniak M, Balyasnikova I. STMC-33. DIFFERENTIAL MIGRATION PATHWAYS OF THERAPEUTIC STEM CELL CARRIERS TO GLIOMA AFTER INTRANASAL DELIVERY Neuro-Oncology. 18: vi189-vi189. DOI: 10.1093/Neuonc/Now212.796 |
0.391 |
|
| 2016 |
Kim JW, Kane J, Young J, Yu D, Miska J, Chang A, Rashidi A, Ahmed A, Balyasnikova I, Lesniak M. IMST-46. DENDRITIC CELL-BASED IMMUNOTHERAPY FOR MALIGNANT GLIOMA BY WAY OF A NOVEL DENDRITIC CELL-TARGETED (scFvDEC205) ADENOVIRAL VECTOR Neuro-Oncology. 18: vi97-vi97. DOI: 10.1093/Neuonc/Now212.402 |
0.376 |
|
| 2016 |
Majid AA, Mooney R, Gilchrist M, Lesniak M, Aboody K. 208. Neural Stem Cell Mediated Oncolytic Virotherapy for Ovarian Cancer Molecular Therapy. 24: S81. DOI: 10.1016/S1525-0016(16)33017-9 |
0.45 |
|
| 2015 |
Cheng Y, Muroski ME, Petit DC, Mansell R, Vemulkar T, Morshed RA, Han Y, Balyasnikova I, Horbinski C, Huang X, Zhang L, Cowburn RP, Lesniak MS. Rotating magnetic field induced oscillation of magnetic particles for in vivo mechanical destruction of malignant glioma. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26708022 DOI: 10.1016/J.Jconrel.2015.12.028 |
0.304 |
|
| 2015 |
Kim JW, Young JS, Solomaha E, Kanojia D, Lesniak MS, Balyasnikova IV. A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors. Scientific Reports. 5: 18133. PMID 26656559 DOI: 10.1038/Srep18133 |
0.355 |
|
| 2015 |
Kim J, Hall RR, Lesniak MS, Ahmed AU. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions. Viruses. 7: 6200-6217. PMID 26633462 DOI: 10.3390/V7122921 |
0.439 |
|
| 2015 |
Cheng SH, Yu D, Tsai HM, Morshed RA, Kanojia D, Lo LW, Leoni L, Govind Y, Zhang L, Aboody KS, Lesniak MS, Chen CT, Balyasnikova IV. Dynamic In Vivo SPECT Imaging of Neural Stem Cells Functionalized with Radiolabeled Nanoparticles for Tracking of Glioblastoma. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26564318 DOI: 10.2967/Jnumed.115.163006 |
0.37 |
|
| 2015 |
Krenciute G, Krebs S, Torres D, Wu MF, Liu H, Dotti G, Li XN, Lesniak MS, Balyasnikova IV, Gottschalk S. Characterization and Functional Analysis of scFv-Based Cars to Redirect T Cells to IL13Rα2-Positive Glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26514825 DOI: 10.1038/Mt.2015.199 |
0.374 |
|
| 2015 |
Alexiades NG, Auffinger B, Kim CK, Hasan T, Lee G, Deheeger M, Tobias AL, Kim J, Balyasnikova I, Lesniak MS, Aboody K, Ahmed AU. MMP14 as a novel downstream target of VEGFR2 in migratory glioma-tropic neural stem cells. Stem Cell Research. 15: 598-607. PMID 26513555 DOI: 10.1016/J.Scr.2015.10.005 |
0.439 |
|
| 2015 |
Miska J, Lesniak MS. Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme. Ebiomedicine. 2: 774-5. PMID 26425671 DOI: 10.1016/J.Ebiom.2015.08.022 |
0.448 |
|
| 2015 |
Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, M Nettlebeck D, Han Y, Zhang L, Lesniak MS. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. Oncoimmunology. 4: e1022302. PMID 26405578 DOI: 10.1080/2162402X.2015.1022302 |
0.475 |
|
| 2015 |
Kanojia D, Balyasnikova IV, Morshed RA, Frank RT, Yu D, Zhang L, Spencer DA, Kim JW, Han Y, Yu D, Ahmed AU, Aboody KS, Lesniak MS. Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. Stem Cells (Dayton, Ohio). PMID 26260958 DOI: 10.1002/Stem.2109 |
0.403 |
|
| 2015 |
Mehta AI, Linninger A, Lesniak MS, Engelhard HH. Current status of intratumoral therapy for glioblastoma. Journal of Neuro-Oncology. 125: 1-7. PMID 26233248 DOI: 10.1007/S11060-015-1875-1 |
0.389 |
|
| 2015 |
Kim JW, Kane JR, Young JS, Chang A, Kanojia D, Morshed R, Miska J, Ahmed A, Balyasnikova I, Han Y, Zhang L, Curiel D, Lesniak MS. A Genetically Modified Adenoviral Vector with a Phage Display Derived Peptide Incorporated into Fiber Fibritin Chimera Prolongs Survival in Experimental Glioma. Human Gene Therapy. PMID 26058317 DOI: 10.1089/Hum.2015.008 |
0.361 |
|
| 2015 |
Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence. Expert Review of Neurotherapeutics. 15: 741-52. PMID 26027432 DOI: 10.1586/14737175.2015.1051968 |
0.429 |
|
| 2015 |
Dey M, Chang AL, Miska J, Wainwright DA, Ahmed AU, Balyasnikova IV, Pytel P, Han Y, Tobias A, Zhang L, Qiao J, Lesniak MS. Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma. Journal of Immunology (Baltimore, Md. : 1950). 195: 367-76. PMID 26026061 DOI: 10.4049/Jimmunol.1401607 |
0.394 |
|
| 2015 |
Spencer DA, Young JS, Kanojia D, Kim JW, Polster SP, Murphy JP, Lesniak MS. Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Therapeutic Delivery. 6: 453-68. PMID 25996044 DOI: 10.4155/Tde.14.123 |
0.378 |
|
| 2015 |
Kim JW, Kane JR, Young JS, Chang AL, Kanojia D, Qian S, Spencer DA, Ahmed AU, Lesniak MS. Neural stem cell-mediated delivery of oncolytic adenovirus. Current Protocols in Human Genetics / Editorial Board, Jonathan L. Haines ... [Et Al.]. 85: 13.11.1-9. PMID 25827347 DOI: 10.1002/0471142905.Hg1311S85 |
0.367 |
|
| 2015 |
Kane JR, Miska J, Young JS, Kanojia D, Kim JW, Lesniak MS. Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro-Oncology. 17: ii24-ii36. PMID 25746089 DOI: 10.1093/Neuonc/Nou355 |
0.385 |
|
| 2015 |
Kanojia D, Morshed RA, Zhang L, Miska JM, Qiao J, Kim JW, Pytel P, Balyasnikova IV, Lesniak MS, Ahmed AU. βIII-Tubulin Regulates Breast Cancer Metastases to the Brain. Molecular Cancer Therapeutics. 14: 1152-61. PMID 25724666 DOI: 10.1158/1535-7163.Mct-14-0950 |
0.347 |
|
| 2015 |
Morshed RA, Gutova M, Juliano J, Barish ME, Hawkins-Daarud A, Oganesyan D, Vazgen K, Yang T, Annala A, Ahmed AU, Aboody KS, Swanson KR, Moats RA, Lesniak MS. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Therapy. 22: 55-61. PMID 25525033 DOI: 10.1038/Cgt.2014.72 |
0.429 |
|
| 2015 |
Zhai L, Lauing KL, Chang AL, Dey M, Qian J, Cheng Y, Lesniak MS, Wainwright DA. The role of IDO in brain tumor immunotherapy. Journal of Neuro-Oncology. 123: 395-403. PMID 25519303 DOI: 10.1007/S11060-014-1687-8 |
0.434 |
|
| 2015 |
Dey M, Ahmed AU, Lesniak MS. Cytomegalovirus and glioma: putting the cart before the horse. Journal of Neurology, Neurosurgery, and Psychiatry. 86: 191-9. PMID 24906494 DOI: 10.1136/Jnnp-2014-307727 |
0.364 |
|
| 2015 |
Chang AL, Miska J, Wainwright DA, Dey M, Qiao J, Pytel P, Han Y, Zhang L, Balyasnikova IV, Ahmed AU, Lesniak MS. Glioma microenvironment-derived CCL2 recruits regulatory T cells and myeloid-derived suppressor cells Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P72 |
0.417 |
|
| 2015 |
Miska J, Chang AL, Rashidi A, Dey M, Han Y, Zhang L, Balyasnikova IV, Ahmed AU, Lesniak MS. The use of anti-GITR antibody treatment in a murine model of glioblastoma multiforme Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P236 |
0.425 |
|
| 2015 |
Yu D, Cheng S, Tsai H, Kanojia D, Leoni L, Aboody K, Chen C, Lesniak M, Balyasnikova I. BMET-40NANO PLATFORM FOR DYNAMIC IN VIVO TRACKING OF NEURAL STEM CELLS TO BRAIN METASTASES OF BREAST CANCER Neuro-Oncology. 17: v53.5-v54. DOI: 10.1093/Neuonc/Nov208.40 |
0.413 |
|
| 2015 |
Kim JW, Kane JR, Young JS, Yu D, Miska J, Chang AL, Rashidi A, Ahmed A, Balyasnikova I, Lesniak MS. ATPS-41DENDRITIC CELL BASED IMMUNOTHERAPY OF MALIGNANT GLIOMA VIA A NOVEL CD8α+ DC TARGETED ADENOVIRAL VECTOR Neuro-Oncology. 17: v27.2-v27. DOI: 10.1093/Neuonc/Nov204.41 |
0.371 |
|
| 2015 |
Krenciute G, Krebs S, Torres D, Lesniak M, Balyasnikova I, Gottschalk S. IM-02 * A scFv-BASED CAR TO REDIRECT T CELLS TO IL13R 2-POSITIVE PEDIATRIC GLIOMA Neuro-Oncology. 17: iii15-iii15. DOI: 10.1093/Neuonc/Nov061.57 |
0.403 |
|
| 2015 |
Krenciute G, Krebs S, Torres D, Lesniak M, Balyasnikova I, Gottschalk S. 282. A scFv-Based CAR To Redirect T Cells To IL13Ra2-Positive Glioma Molecular Therapy. 23: S113. DOI: 10.1016/S1525-0016(16)33891-6 |
0.373 |
|
| 2015 |
Kim JW, Young JS, Lesniak MS, Balyasnikova IV. 22. A Novel Single-Chain Antibody for Selective Targeting of IL13Ra2-Expressing Brain Tumors Molecular Therapy. 23: S10. DOI: 10.1016/S1525-0016(16)33626-7 |
0.374 |
|
| 2014 |
Deheeger M, Lesniak MS, Ahmed AU. Cellular plasticity regulated cancer stem cell niche: a possible new mechanism of chemoresistance. Cancer Cell & Microenvironment. 1. PMID 26161429 DOI: 10.14800/Ccm.295 |
0.458 |
|
| 2014 |
Cheng Y, Dai Q, Morshed RA, Fan X, Wegscheid ML, Wainwright DA, Han Y, Zhang L, Auffinger B, Tobias AL, Rincón E, Thaci B, Ahmed AU, Warnke PC, He C, ... Lesniak MS, et al. Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small (Weinheim An Der Bergstrasse, Germany). 10: 5137-50. PMID 25104165 DOI: 10.1002/Smll.201400654 |
0.371 |
|
| 2014 |
Wainwright DA, Lesniak MS. Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma. Oncoimmunology. 3: e28927. PMID 25057450 DOI: 10.4161/Onci.28927 |
0.418 |
|
| 2014 |
Lukas RV, Lesniak MS, Salgia R. Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. Cns Oncology. 3: 61-75. PMID 25054901 DOI: 10.2217/Cns.13.66 |
0.362 |
|
| 2014 |
Young JS, Morshed RA, Kim JW, Balyasnikova IV, Ahmed AU, Lesniak MS. Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy. Expert Opinion On Drug Delivery. 11: 1733-46. PMID 25005767 DOI: 10.1517/17425247.2014.937420 |
0.463 |
|
| 2014 |
Young JS, Kim JW, Ahmed AU, Lesniak MS. Therapeutic cell carriers: a potential road to cure glioma. Expert Review of Neurotherapeutics. 14: 651-60. PMID 24852229 DOI: 10.1586/14737175.2014.917964 |
0.487 |
|
| 2014 |
Wegscheid ML, Morshed RA, Cheng Y, Lesniak MS. The art of attraction: applications of multifunctional magnetic nanomaterials for malignant glioma. Expert Opinion On Drug Delivery. 11: 957-75. PMID 24766329 DOI: 10.1517/17425247.2014.912629 |
0.417 |
|
| 2014 |
Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, Cheng Y, Kim JW, Qiao J, Zhang L, Han Y, Lesniak MS. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5290-301. PMID 24691018 DOI: 10.1158/1078-0432.Ccr-14-0514 |
0.407 |
|
| 2014 |
Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, Lesniak MS, Ahmed AU. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death and Differentiation. 21: 1119-31. PMID 24608791 DOI: 10.1038/Cdd.2014.31 |
0.48 |
|
| 2014 |
Lesniak MS. Development of preclinical models for immunogene therapy of brain cancer: it's not monkey business! Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 247-9. PMID 24487565 DOI: 10.1038/Mt.2013.298 |
0.344 |
|
| 2014 |
Thaci B, Ahmed AU, Ulasov IV, Wainwright DA, Nigam P, Auffinger B, Tobias AL, Han Y, Zhang L, Moon KS, Lesniak MS. Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma. Cancer Gene Therapy. 21: 38-44. PMID 24434573 DOI: 10.1038/Cgt.2013.81 |
0.405 |
|
| 2014 |
Dey M, Chang AL, Wainwright DA, Ahmed AU, Han Y, Balyasnikova IV, Lesniak MS. Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model. Journal of Neuroimmunology. 266: 33-42. PMID 24268287 DOI: 10.1016/J.Jneuroim.2013.10.012 |
0.4 |
|
| 2014 |
Chung EJ, Cheng Y, Morshed R, Nord K, Han Y, Wegscheid ML, Auffinger B, Wainwright DA, Lesniak MS, Tirrell MV. Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials. 35: 1249-56. PMID 24211079 DOI: 10.1016/J.Biomaterials.2013.10.064 |
0.374 |
|
| 2014 |
Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS. Multifunctional nanoparticles for brain tumor imaging and therapy. Advanced Drug Delivery Reviews. 66: 42-57. PMID 24060923 DOI: 10.1016/J.Addr.2013.09.006 |
0.426 |
|
| 2014 |
Balyasnikova IV, Prasol MS, Ferguson SD, Han Y, Ahmed AU, Gutova M, Tobias AL, Mustafi D, Rincón E, Zhang L, Aboody KS, Lesniak MS. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 140-8. PMID 24002694 DOI: 10.1038/Mt.2013.199 |
0.797 |
|
| 2014 |
Moon K, Wainwright DA, Balyasnikova IV, Kim CK, Ko YS, Kim KK, Lesniak MS. Abstract LB-64: Immune modulatory effects of mesenchymal stem cells on regulatory T cells in mouse glioma model Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-64 |
0.439 |
|
| 2014 |
Auffinger B, Tobias AL, Han Y, Lesniak MS, Ahmed AU. Abstract 3899: ROCK inhibitor as a differentiation-inducing agent to target glioma stem cells Cancer Research. 74: 3899-3899. DOI: 10.1158/1538-7445.Am2014-3899 |
0.444 |
|
| 2014 |
Sengupta S, Balyasnikova I, Naheed S, Lesniak MS, Junghans RP, Sampath P. Abstract 2798: Targeting IL13R alpha2 heterogeneity in malignant glioma with engineered T cells Cancer Research. 74: 2798-2798. DOI: 10.1158/1538-7445.Am2014-2798 |
0.46 |
|
| 2014 |
Kanojia DP, Sarvaiya P, Qiao J, Zhang L, Balyasnikova I, Lesniak MS. Abstract 2006: The role of neuronal predominant gene expression in breast cancer brain metastasis Cancer Research. 74: 2006-2006. DOI: 10.1158/1538-7445.Am2014-2006 |
0.342 |
|
| 2014 |
Chang AL, Wainwright DA, Dey M, Han Y, Lesniak MS. Abstract 1091: CCR4+ regulatory T cells progressively accumulate in the presence of leukocyte-derived CCL22/CCL17 in an experimental model of glioblastoma multiforme Cancer Research. 74: 1091-1091. DOI: 10.1158/1538-7445.Am2014-1091 |
0.428 |
|
| 2014 |
Dey M, Chang A, Wainwright D, Ahmed A, Han Y, Lesniak M. IT-07 * COMPARATIVE EVALUATION OF pDCs AND mDCs FOR DENDRITIC CELL BASED VACCINE STRATEGY FOR MALIGNANT GLIOMA Neuro-Oncology. 16: v111-v111. DOI: 10.1093/Neuonc/Nou258.6 |
0.389 |
|
| 2014 |
Qiao J, Dey M, Chang A, Woongki K, Han Y, Zhang L, Lesniak M. IT-27 * ONCOLYTIC ADENOVIRUSES-MEDIATED IMMUNE RESPONSES IN SYNGENEIC MURINE GLIOMA MODEL Neuro-Oncology. 16: v115-v115. DOI: 10.1093/Neuonc/Nou258.25 |
0.401 |
|
| 2014 |
Balyasnikova I, Dey M, Tobias A, Kanojia D, Lee G, Han Y, Zhang L, Ahmed A, Aboody K, Lesniak M. ET-05 * INTRANASAL DELIVERY OF NEURAL STEM CELLS LOADED WITH ONCOLYTIC ADENOVIRUS EXTENDS SURVIVAL OF MICE WITH INTRACRANIAL GLIOMA Neuro-Oncology. 16: v79-v80. DOI: 10.1093/Neuonc/Nou255.5 |
0.447 |
|
| 2014 |
Kim JW, Kane JR, Young JS, Morshed RA, Chang AA, Ahmed AU, Balyasnikova IV, Lesniak MS. ET-29 * AN OPTIMIZED ONCOLYTIC ADENOVIRUS FOR GLIOMA THERAPY: SPECIFIC TARGETING, EFFICIENT INFECTION, AND RESTRICTED REPLICATION IN GLIOMA Neuro-Oncology. 16: v85-v86. DOI: 10.1093/Neuonc/Nou255.29 |
0.401 |
|
| 2013 |
Dey M, Auffinger B, Lesniak MS, Ahmed AU. Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making? Future Virology. 8: 675-693. PMID 24910708 DOI: 10.2217/Fvl.13.47 |
0.411 |
|
| 2013 |
Morshed RA, Cheng Y, Auffinger B, Wegscheid ML, Lesniak MS. The potential of polymeric micelles in the context of glioblastoma therapy. Frontiers in Pharmacology. 4: 157. PMID 24416018 DOI: 10.3389/Fphar.2013.00157 |
0.445 |
|
| 2013 |
Sarvaiya PJ, Guo D, Ulasov I, Gabikian P, Lesniak MS. Chemokines in tumor progression and metastasis. Oncotarget. 4: 2171-85. PMID 24259307 DOI: 10.18632/Oncotarget.1426 |
0.347 |
|
| 2013 |
Ulasov I, Thaci B, Sarvaiya P, Yi R, Guo D, Auffinger B, Pytel P, Zhang L, Kim CK, Borovjagin A, Dey M, Han Y, Baryshnikov AY, Lesniak MS. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. Cancer Medicine. 2: 457-67. PMID 24156018 DOI: 10.1002/Cam4.104 |
0.337 |
|
| 2013 |
Gutova M, Frank JA, D'Apuzzo M, Khankaldyyan V, Gilchrist MM, Annala AJ, Metz MZ, Abramyants Y, Herrmann KA, Ghoda LY, Najbauer J, Brown CE, Blanchard MS, Lesniak MS, Kim SU, et al. Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use. Stem Cells Translational Medicine. 2: 766-75. PMID 24014682 DOI: 10.5966/Sctm.2013-0049 |
0.425 |
|
| 2013 |
Tobias AL, Thaci B, Auffinger B, Rincón E, Balyasnikova IV, Kim CK, Han Y, Zhang L, Aboody KS, Ahmed AU, Lesniak MS. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Translational Medicine. 2: 655-66. PMID 23926209 DOI: 10.5966/Sctm.2013-0039 |
0.421 |
|
| 2013 |
Kim CK, Ahmed AU, Auffinger B, Ulasov IV, Tobias AL, Moon KS, Lesniak MS. N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 2063-73. PMID 23883863 DOI: 10.1038/Mt.2013.179 |
0.434 |
|
| 2013 |
Cheng Y, Morshed R, Cheng SH, Tobias A, Auffinger B, Wainwright DA, Zhang L, Yunis C, Han Y, Chen CT, Lo LW, Aboody KS, Ahmed AU, Lesniak MS. Nanoparticle-programmed self-destructive neural stem cells for glioblastoma targeting and therapy. Small (Weinheim An Der Bergstrasse, Germany). 9: 4123-9. PMID 23873826 DOI: 10.1002/Smll.201301111 |
0.378 |
|
| 2013 |
Ahmed AU, Thaci B, Tobias AL, Auffinger B, Zhang L, Cheng Y, Kim CK, Yunis C, Han Y, Alexiades NG, Fan X, Aboody KS, Lesniak MS. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. Journal of the National Cancer Institute. 105: 968-77. PMID 23821758 DOI: 10.1093/Jnci/Djt141 |
0.502 |
|
| 2013 |
Wainwright DA, Dey M, Chang A, Lesniak MS. Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Frontiers in Immunology. 4: 116. PMID 23720663 DOI: 10.3389/Fimmu.2013.00116 |
0.437 |
|
| 2013 |
Abel TJ, Ryken T, Lesniak MS, Gabikian P. Gliadel for brain metastasis. Surgical Neurology International. 4: S289-93. PMID 23717799 DOI: 10.4103/2152-7806.111305 |
0.353 |
|
| 2013 |
Ahmed AU, Auffinger B, Lesniak MS. Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. Expert Review of Neurotherapeutics. 13: 545-55. PMID 23621311 DOI: 10.1586/Ern.13.42 |
0.463 |
|
| 2013 |
Auffinger B, Morshed R, Tobias A, Cheng Y, Ahmed AU, Lesniak MS. Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma? Oncotarget. 4: 378-96. PMID 23594406 DOI: 10.18632/Oncotarget.937 |
0.427 |
|
| 2013 |
Auffinger B, Ahmed AU, Lesniak MS. Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice. Frontiers in Oncology. 3: 32. PMID 23443138 DOI: 10.3389/Fonc.2013.00032 |
0.44 |
|
| 2013 |
McDermott R, Gabikian P, Sarvaiya P, Ulasov I, Lesniak MS. MicroRNAs in brain metastases: big things come in small packages. Journal of Molecular Medicine (Berlin, Germany). 91: 5-13. PMID 23138927 DOI: 10.1007/S00109-012-0971-3 |
0.431 |
|
| 2013 |
Tobias A, Ahmed A, Moon KS, Lesniak MS. The art of gene therapy for glioma: a review of the challenging road to the bedside. Journal of Neurology, Neurosurgery, and Psychiatry. 84: 213-22. PMID 22993449 DOI: 10.1136/Jnnp-2012-302946 |
0.349 |
|
| 2013 |
Auffinger B, Thaci B, Ahmed A, Ulasov I, Lesniak MS. MicroRNA targeting as a therapeutic strategy against glioma. Current Molecular Medicine. 13: 535-42. PMID 22934848 DOI: 10.2174/1566524011313040006 |
0.424 |
|
| 2013 |
Ahmed AU, Auffinger B, Tobias A, Thaci B, Han Y, Lesniak MS. Abstract 5021: Temozolomide-induced conversion of glioma cells into glioma “stem-like” cells with enhanced invasion properties. Cancer Research. 73: 5021-5021. DOI: 10.1158/1538-7445.Am2013-5021 |
0.491 |
|
| 2013 |
Chang A, Wainwright D, Dey M, Han Y, Lesniak M. Ir-003. Ccr4+ Regulatory T Cells Accumulate Within The Brain Tumor In An Experimental Model Of Gbm Neuro-Oncology. 15. DOI: 10.1093/Neuonc/Not177.257 |
0.407 |
|
| 2013 |
Aaberg-Jessen C, Fogh L, Halle B, Jensen V, Brunner N, Kristensen BW, Abe T, Momii Y, Watanabe J, Morisaki I, Natsume A, Wakabayashi T, Fujiki M, Aldaz B, Fabius AWM, ... ... Lesniak MS, ... ... Lesniak M, et al. EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 15: iii37-iii61. DOI: 10.1093/Neuonc/Not176 |
0.74 |
|
| 2012 |
Auffinger B, Thaci B, Nigam P, Rincon E, Cheng Y, Lesniak MS. New therapeutic approaches for malignant glioma: in search of the Rosetta stone. F1000 Medicine Reports. 4: 18. PMID 22991580 DOI: 10.3410/M4-18 |
0.444 |
|
| 2012 |
Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6110-21. PMID 22932670 DOI: 10.1158/1078-0432.Ccr-12-2130 |
0.442 |
|
| 2012 |
Balyasnikova IV, Wainwright DA, Solomaha E, Lee G, Han Y, Thaci B, Lesniak MS. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2. The Journal of Biological Chemistry. 287: 30215-27. PMID 22778273 DOI: 10.1074/Jbc.M112.370015 |
0.363 |
|
| 2012 |
Rolle CE, Sengupta S, Lesniak MS. Mechanisms of immune evasion by gliomas. Advances in Experimental Medicine and Biology. 746: 53-76. PMID 22639159 DOI: 10.1007/978-1-4614-3146-6_5 |
0.388 |
|
| 2012 |
Thaci B, Ahmed AU, Ulasov IV, Tobias AL, Han Y, Aboody KS, Lesniak MS. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Therapy. 19: 431-42. PMID 22555507 DOI: 10.1038/Cgt.2012.21 |
0.477 |
|
| 2012 |
Wainwright DA, Nigam P, Thaci B, Dey M, Lesniak MS. Recent developments on immunotherapy for brain cancer. Expert Opinion On Emerging Drugs. 17: 181-202. PMID 22533851 DOI: 10.1517/14728214.2012.679929 |
0.432 |
|
| 2012 |
Yun J, Sonabend AM, Ulasov IV, Kim DH, Rozhkova EA, Novosad V, Dashnaw S, Brown T, Canoll P, Bruce JN, Lesniak MS. A novel adenoviral vector labeled with superparamagnetic iron oxide nanoparticles for real-time tracking of viral delivery. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 19: 875-80. PMID 22516547 DOI: 10.1016/J.Jocn.2011.12.016 |
0.333 |
|
| 2012 |
Ahmed AU, Ulasov IV, Mercer RW, Lesniak MS. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods in Molecular Biology (Clifton, N.J.). 797: 97-109. PMID 21948472 DOI: 10.1007/978-1-61779-340-0_8 |
0.484 |
|
| 2012 |
Hashemi Sadraei N, Ulasov I, Burgett M, Nowacki AS, Prayson R, Weil RJ, Kar N, Ahluwalia MS, Muller-Greven G, Shi T, Lesniak MS, Gladson C. FIP200 and Rb1 expression in CNS metastasis from breast cancer (CNS met): Potential predictors of patient outcome. Journal of Clinical Oncology. 30: 2014-2014. DOI: 10.1200/Jco.2012.30.15_Suppl.2014 |
0.308 |
|
| 2012 |
Ulasov I, Auffinger B, Thaçi B, Pytel P, Kaverina N, Liu F, Ahmed A, Lesniak M. Abstract 880: Inhibition of MMP14 potentiates the antiglioma effect of TMZ and ionizing radiation Cancer Research. 72: 880-880. DOI: 10.1158/1538-7445.Am2012-880 |
0.327 |
|
| 2012 |
Prasol MS, Moon K, Lesniak MS, Balyasnikova IV. Abstract 4315: A novel role for the high affinity IL13 receptor in glioblastoma multiforme Cancer Research. 72: 4315-4315. DOI: 10.1158/1538-7445.Am2012-4315 |
0.755 |
|
| 2012 |
Ahmed AU, Thaci B, Tobias A, Alexiades NG, Han Y, Ulasov II, Aboody K, Lesniak MS. Abstract 3487: Distant delivery of glioma-restricted oncolytic adenovirus loaded into a neural stem cell-based carrier prolongs the survival of animals with human glioblastoma Cancer Research. 72: 3487-3487. DOI: 10.1158/1538-7445.Am2012-3487 |
0.501 |
|
| 2012 |
Kozono D, Nitta M, Sampetrean O, Kimberly N, Kushwaha D, Merzon D, Ligon K, Zhu S, Zhu K, Kim TH, Kwon C, Becher O, Saya H, Chen CC, Donovan LK, ... ... Lesniak MS, et al. LAB-STEM CELLS Neuro-Oncology. 14: vi142-vi152. DOI: 10.1093/Neuonc/Nos239 |
0.757 |
|
| 2012 |
Proescholdt MA, Merrill MJ, Stoerr E, Lohmeier A, Brawanski A, Sim H, Hu B, Pineda CA, Yoon S, Viapiano MS, Rajappa P, Cobb WS, Huang Y, Lyden DC, Bromberg J, ... ... Lesniak M, et al. LAB-ANGIOGENESIS AND INVASION Neuro-Oncology. 14: vi1-vi6. DOI: 10.1093/Neuonc/Nos219 |
0.338 |
|
| 2012 |
Wainwright D, Balyasnikova I, Ahmed A, Auffinger B, Han Y, Lesniak M. 46. Upregulation of indoleamine 2,3-dioxygenase in brain tumors is associated with decreased survival through a T cell-dependent mechanism Brain, Behavior, and Immunity. 26: S13. DOI: 10.1016/J.Bbi.2012.07.070 |
0.45 |
|
| 2011 |
Wainwright DA, Sengupta S, Han Y, Lesniak MS. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro-Oncology. 13: 1308-23. PMID 21908444 DOI: 10.1093/Neuonc/Nor134 |
0.453 |
|
| 2011 |
Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS. Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer Letters. 310: 148-59. PMID 21802840 DOI: 10.1016/J.Canlet.2011.06.029 |
0.446 |
|
| 2011 |
Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, Lesniak MS. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Molecular Pharmaceutics. 8: 1559-72. PMID 21718006 DOI: 10.1021/mp200161f |
0.385 |
|
| 2011 |
Lesniak MS. Immunotherapy for glioblastoma: the devil is in the details. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3105; author reply 3. PMID 21709193 DOI: 10.1200/Jco.2011.34.9019 |
0.329 |
|
| 2011 |
Ahmed AU, Lesniak MS. Glioblastoma multiforme: can neural stem cells deliver the therapeutic payload and fulfill the clinical promise? Expert Review of Neurotherapeutics. 11: 775-7. PMID 21651324 DOI: 10.1586/Ern.11.65 |
0.424 |
|
| 2011 |
Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F, Balyasnikova IV, Ulasov IY, Aboody KS, Lesniak MS. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1714-26. PMID 21629227 DOI: 10.1038/mt.2011.100 |
0.368 |
|
| 2011 |
Wainwright DA, Balyasnikova IV, Han Y, Lesniak MS. The expression of BST2 in human and experimental mouse brain tumors. Experimental and Molecular Pathology. 91: 440-6. PMID 21565182 DOI: 10.1016/J.Yexmp.2011.04.012 |
0.453 |
|
| 2011 |
Sengupta S, Ulasov IV, Thaci B, Ahmed AU, Lesniak MS. Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells. Plos One. 6: e18091. PMID 21464908 DOI: 10.1371/Journal.Pone.0018091 |
0.337 |
|
| 2011 |
Nicholas MK, Lukas RV, Chmura S, Yamini B, Lesniak M, Pytel P. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Seminars in Oncology. 38: 243-53. PMID 21421114 DOI: 10.1053/J.Seminoncol.2011.01.009 |
0.354 |
|
| 2011 |
Thaci B, Ulasov IV, Wainwright DA, Lesniak MS. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget. 2: 113-21. PMID 21399236 DOI: 10.18632/Oncotarget.231 |
0.323 |
|
| 2011 |
Ulasov IV, Nandi S, Dey M, Sonabend AM, Lesniak MS. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Molecular Medicine (Cambridge, Mass.). 17: 103-12. PMID 20957337 DOI: 10.2119/Molmed.2010.00062 |
0.365 |
|
| 2011 |
Dey M, Ulasov IV, Tyler MA, Sonabend AM, Lesniak MS. Cancer stem cells: the final frontier for glioma virotherapy. Stem Cell Reviews. 7: 119-29. PMID 20237963 DOI: 10.1007/S12015-010-9132-7 |
0.449 |
|
| 2011 |
Balyasnikova I, Ferguson S, Han Y, Lesniak M. Abstract 3323: Neural stem cells expressing TRAIL as therapeutic modality for treatment of experimental malignant glioma Cancer Research. 71: 3323-3323. DOI: 10.1158/1538-7445.Am2011-3323 |
0.441 |
|
| 2011 |
Ulasov IV, Kaverina N, Thaci B, Pytel P, Sattar H, Cao D, Hurst DR, Welch DR, Olopade OI, Kadagidze ZG, Lesniak MS. Abstract 1439: Clinical significance of KISS1 protein expression in breast cancer metastasis to brain Cancer Research. 71: 1439-1439. DOI: 10.1158/1538-7445.Am2011-1439 |
0.339 |
|
| 2011 |
Wainwright D, Sengupta S, Han Y, Lesniak M. 156. Thymus-derived rather than tumor-induced regulatory T cells predominate in human and experimental mouse brain tumors Brain, Behavior, and Immunity. 25: S224. DOI: 10.1016/J.Bbi.2011.07.159 |
0.431 |
|
| 2010 |
Wainwright DA, Sengupta S, Han Y, Ulasov IV, Lesniak MS. The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. Plos One. 5: e15390. PMID 21060663 DOI: 10.1371/Journal.Pone.0015390 |
0.385 |
|
| 2010 |
Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia (New York, N.Y.). 12: 837-47. PMID 20927322 DOI: 10.1593/Neo.10662 |
0.454 |
|
| 2010 |
Ahmed AU, Alexiades NG, Lesniak MS. The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Current Opinion in Molecular Therapeutics. 12: 546-52. PMID 20886386 |
0.372 |
|
| 2010 |
Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, ... ... Lesniak MS, et al. The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacology & Therapeutics. 128: 375-84. PMID 20732354 DOI: 10.1016/J.Pharmthera.2010.08.001 |
0.376 |
|
| 2010 |
Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Gupta P, Emdad L, Lebedeva IV, Sauane M, Su ZZ, Rahmani M, Broaddus WC, Young HF, ... Lesniak M, et al. MDA-7/IL-24 as a cancer therapeutic: from bench to bedside. Anti-Cancer Drugs. 21: 725-31. PMID 20613485 DOI: 10.1097/Cad.0B013E32833Cfbe1 |
0.36 |
|
| 2010 |
Ahmed AU, Rolle CE, Tyler MA, Han Y, Sengupta S, Wainwright DA, Balyasnikova IV, Ulasov IV, Lesniak MS. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1846-56. PMID 20588259 DOI: 10.1038/Mt.2010.131 |
0.342 |
|
| 2010 |
Ferguson SD, Ahmed AU, Thaci B, Mercer RW, Lesniak MS. Crossing the boundaries: stem cells and gene therapy. Discovery Medicine. 9: 192-6. PMID 20350484 |
0.344 |
|
| 2010 |
Balyasnikova IV, Ferguson SD, Sengupta S, Han Y, Lesniak MS. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. Plos One. 5: e9750. PMID 20305783 DOI: 10.1371/Journal.Pone.0009750 |
0.479 |
|
| 2010 |
Ferguson SD, Musleh W, Gurbuxani S, Shafizadeh SF, Lesniak MS. Intracranial mucosa-associated lymphoid tissue (MALT) lymphoma. Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia. 17: 666-9. PMID 20202849 DOI: 10.1016/J.Jocn.2009.10.001 |
0.306 |
|
| 2010 |
Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1130-42. PMID 20179672 DOI: 10.1038/Mt.2010.29 |
0.373 |
|
| 2010 |
Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, Grant S, Curiel DT, Fisher PB, Dent P. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Research. 70: 1120-9. PMID 20103619 DOI: 10.1158/0008-5472.Can-09-4043 |
0.393 |
|
| 2010 |
Kim DH, Rozhkova EA, Ulasov IV, Bader SD, Rajh T, Lesniak MS, Novosad V. Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nature Materials. 9: 165-71. PMID 19946279 DOI: 10.1038/Nmat2591 |
0.358 |
|
| 2010 |
Rolle CE, Sengupta S, Lesniak MS. Challenges in clinical design of immunotherapy trials for malignant glioma. Neurosurgery Clinics of North America. 21: 201-14. PMID 19944979 DOI: 10.1016/J.Nec.2009.08.002 |
0.425 |
|
| 2010 |
Balyasnikova IV, Franco-Gou R, Mathis JM, Lesniak MS. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. Journal of Tissue Engineering and Regenerative Medicine. 4: 247-58. PMID 19937911 DOI: 10.1002/Term.228 |
0.432 |
|
| 2010 |
Dey M, Ulasov IV, Lesniak MS. Virotherapy against malignant glioma stem cells. Cancer Letters. 289: 1-10. PMID 19643532 DOI: 10.1016/J.Canlet.2009.04.045 |
0.424 |
|
| 2009 |
Kranzler J, Tyler MA, Sonabend AM, Ulasov IV, Lesniak MS. Stem cells as delivery vehicles for oncolytic adenoviral virotherapy. Current Gene Therapy. 9: 389-95. PMID 19860653 DOI: 10.2174/156652309789753347 |
0.509 |
|
| 2009 |
Rozhkova EA, Ulasov I, Lai B, Dimitrijevic NM, Lesniak MS, Rajh T. A high-performance nanobio photocatalyst for targeted brain cancer therapy. Nano Letters. 9: 3337-42. PMID 19640002 DOI: 10.1021/Nl901610F |
0.338 |
|
| 2009 |
Nandi S, Lesniak MS. Adenoviral virotherapy for malignant brain tumors. Expert Opinion On Biological Therapy. 9: 737-47. PMID 19456208 DOI: 10.1517/14712590902988451 |
0.443 |
|
| 2009 |
Tyler MA, Ulasov IV, Lesniak MS. Cancer cell death by design: apoptosis, autophagy and glioma virotherapy. Autophagy. 5: 856-7. PMID 19430207 DOI: 10.4161/Auto.8792 |
0.334 |
|
| 2009 |
Sugihara AQ, Rolle CE, Lesniak MS. Regulatory T cells actively infiltrate metastatic brain tumors. International Journal of Oncology. 34: 1533-40. PMID 19424570 DOI: 10.3892/Ijo_00000282 |
0.438 |
|
| 2009 |
Mercer RW, Tyler MA, Ulasov IV, Lesniak MS. Targeted therapies for malignant glioma: progress and potential. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 23: 25-35. PMID 19344189 DOI: 10.2165/00063030-200923010-00003 |
0.344 |
|
| 2009 |
Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. British Journal of Cancer. 100: 1154-64. PMID 19277041 DOI: 10.1038/Sj.Bjc.6604969 |
0.379 |
|
| 2009 |
Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC, Lesniak MS. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. International Journal of Oncology. 34: 729-42. PMID 19212678 DOI: 10.3892/Ijo_00000199 |
0.373 |
|
| 2009 |
Tyler MA, Ulasov IV, Sonabend AM, Nandi S, Han Y, Marler S, Roth J, Lesniak MS. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Therapy. 16: 262-78. PMID 19078993 DOI: 10.1038/Gt.2008.165 |
0.447 |
|
| 2009 |
Sengupta S, Nandi S, Rolle CE, Han Y, Lesniak MS. Abstract A36: Fibronectin promotes glioma progression by modulating survivin expression and regulatory T cell infiltration Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A36 |
0.476 |
|
| 2009 |
Sonabend AM, Ulasov IV, Dana K, Lesniak MS. Gene therapy for malignant glioma Therapeutic Ribonucleic Acids in Brain Tumors. 103-124. DOI: 10.1007/978-3-642-00475-9_5 |
0.382 |
|
| 2008 |
Paul CP, Everts M, Glasgow JN, Dent P, Fisher PB, Ulasov IV, Lesniak MS, Stoff-Khalili MA, Roth JC, Preuss MA, Dirven CM, Lamfers ML, Siegal GP, Zhu ZB, Curiel DT. Characterization of infectivity of knob-modified adenoviral vectors in glioma. Cancer Biology & Therapy. 7: 786-93. PMID 18756624 DOI: 10.4161/Cbt.7.5.5421 |
0.369 |
|
| 2008 |
Ulasov IV, Tyler MA, Rivera AA, Nettlebeck DM, Douglas JT, Lesniak MS. Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy. Journal of Medical Virology. 80: 1595-603. PMID 18649343 DOI: 10.1002/Jmv.21264 |
0.343 |
|
| 2008 |
Nandi S, Ulasov IV, Tyler MA, Sugihara AQ, Molinero L, Han Y, Zhu ZB, Lesniak MS. Low-dose radiation enhances survivin-mediated virotherapy against malignant glioma stem cells. Cancer Research. 68: 5778-84. PMID 18632631 DOI: 10.1158/0008-5472.Can-07-6441 |
0.374 |
|
| 2008 |
Sonabend AM, Rolle CE, Lesniak MS. The role of regulatory T cells in malignant glioma. Anticancer Research. 28: 1143-50. PMID 18505050 |
0.332 |
|
| 2008 |
Tyler MA, Sonabend AM, Ulasov IV, Lesniak MS. Vector therapies for malignant glioma: shifting the clinical paradigm. Expert Opinion On Drug Delivery. 5: 445-58. PMID 18426385 DOI: 10.1517/17425247.5.4.445 |
0.362 |
|
| 2008 |
Andaloussi AE, Han Y, Lesniak MS. Progression of intracranial glioma disrupts thymic homeostasis and induces T-cell apoptosis in vivo. Cancer Immunology, Immunotherapy : Cii. 57: 1807-16. PMID 18392618 DOI: 10.1007/S00262-008-0508-3 |
0.371 |
|
| 2008 |
Sonabend AM, Ulasov IV, Tyler MA, Rivera AA, Mathis JM, Lesniak MS. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells (Dayton, Ohio). 26: 831-41. PMID 18192232 DOI: 10.1634/stemcells.2007-0758 |
0.371 |
|
| 2008 |
Sonabend AM, Velicu S, Ulasov IV, Han Y, Tyler B, Brem H, Matar MM, Fewell JG, Anwer K, Lesniak MS. A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anti-Cancer Drugs. 19: 133-42. PMID 18176109 DOI: 10.1097/Cad.0B013E3282F24017 |
0.369 |
|
| 2007 |
Sonabend AM, Lesniak MS, Ulasov IV. Emerging role of new transgenic mouse models in glioma research Expert Review of Anticancer Therapy. 7: S7-S13. PMID 18076321 DOI: 10.1586/14737140.7.12S.S7 |
0.381 |
|
| 2007 |
Sonabend AM, Dana K, Lesniak MS. Targeting epidermal growth factor receptor variant III: A novel strategy for the therapy of malignant glioma Expert Review of Anticancer Therapy. 7: S45-S50. PMID 18076318 DOI: 10.1586/14737140.7.12S.S45 |
0.37 |
|
| 2007 |
Kushen MC, Sonabend AM, Lesniak MS. Current Immunotherapeutic Strategies for Central Nervous System Tumors Surgical Oncology Clinics of North America. 16: 987-1004. PMID 18022555 DOI: 10.1016/J.Soc.2007.07.003 |
0.42 |
|
| 2007 |
Ulasov IV, Rivera AA, Nettelbeck DM, Rivera LB, Mathis JM, Sonabend AM, Tyler M, Wang M, Douglas JT, Lesniak MS. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy. International Journal of Oncology. 31: 1177-85. PMID 17912445 DOI: 10.3892/Ijo.31.5.1177 |
0.462 |
|
| 2007 |
Ulasov IV, Zhu ZB, Tyler MA, Han Y, Rivera AA, Khramtsov A, Curiel DT, Lesniak MS. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma Human Gene Therapy. 18: 589-602. PMID 17630837 DOI: 10.1089/Hum.2007.002 |
0.405 |
|
| 2007 |
Ferguson S, Lesniak MS. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors Current Drug Delivery. 4: 169-180. PMID 17456036 DOI: 10.2174/156720107780362302 |
0.403 |
|
| 2007 |
Ulasov IV, Rivera AA, Sonabend AM, Rivera LB, Wang M, Zhu ZB, Lesniak MS. Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy Cancer Biology and Therapy. 6: 679-685. PMID 17404502 DOI: 10.4161/Cbt.6.5.3957 |
0.355 |
|
| 2007 |
Zheng S, Ulasov IV, Han Y, Tyler MA, Zhu ZB, Lesniak MS. Fiber-knob modifications enhance adenoviral tropism and gene transfer in malignant glioma Journal of Gene Medicine. 9: 151-160. PMID 17351980 DOI: 10.1002/Jgm.1008 |
0.326 |
|
| 2007 |
Ulasov IV, Tyler MA, Han Y, Glasgow JN, Lesniak MS. Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma. Human Gene Therapy. 18: 118-29. PMID 17328684 DOI: 10.1089/Hum.2006.146 |
0.393 |
|
| 2007 |
El Andaloussi A, Lesniak MS. CD4+CD25+FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas Journal of Neuro-Oncology. 83: 145-152. PMID 17216339 DOI: 10.1007/S11060-006-9314-Y |
0.359 |
|
| 2006 |
Musleh W, Sonabend AM, Lesniak MS. Role of craniotomy in the management of pituitary adenomas and sellar/parasellar tumors Expert Review of Anticancer Therapy. 6: S79-S83. PMID 17004861 DOI: 10.1586/14737140.6.9S.S79 |
0.321 |
|
| 2006 |
Sonabend AM, Musleh W, Lesniak MS. Oncogenesis and mutagenesis of pituitary tumors Expert Review of Anticancer Therapy. 6: S3-S14. PMID 17004855 DOI: 10.1586/14737140.6.9S.S3 |
0.379 |
|
| 2006 |
Tyler MA, Ulasov IV, Borovjagin A, Sonabend AM, Khramtsov A, Han Y, Dent P, Fisher PB, Curiel DT, Lesniak MS. Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus Molecular Cancer Therapeutics. 5: 2408-2416. PMID 16985075 DOI: 10.1158/1535-7163.Mct-06-0187 |
0.359 |
|
| 2006 |
Andaloussi AEL, Han YU, Lesniak MS. Prolongation of survival following depletion of CD4+CD25 + regulatory T cells in mice with experimental brain tumors Journal of Neurosurgery. 105: 430-437. PMID 16961139 DOI: 10.3171/Jns.2006.105.3.430 |
0.429 |
|
| 2006 |
El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors Glia. 54: 526-535. PMID 16906541 DOI: 10.1002/Glia.20401 |
0.395 |
|
| 2006 |
El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme Neuro-Oncology. 8: 234-243. PMID 16723631 DOI: 10.1215/15228517-2006-006 |
0.393 |
|
| 2006 |
Ulasov IV, Tyler MA, Zheng S, Han Y, Lesniak MS. CD46 represents a target for adenoviral gene therapy of malignant glioma Human Gene Therapy. 17: 556-564. PMID 16716112 DOI: 10.1089/Hum.2006.17.556 |
0.307 |
|
| 2006 |
Lesniak MS. Gene therapy for malignant glioma. Expert Review of Neurotherapeutics. 6: 479-88. PMID 16623647 DOI: 10.1586/14737175.6.4.479 |
0.329 |
|
| 2006 |
Lesniak MS. Immunotherapy for brain tumors: Quo vadis? Expert Review of Neurotherapeutics. 6: 447-451. PMID 16623643 DOI: 10.1586/14737175.6.4.447 |
0.429 |
|
| 2006 |
Van Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lamfers MLM, Rein D, Lesniak MS, Siegal GP, Dirven CMF, Curiel DT, Zhu ZB. The human survivin promoter: A novel transcriptional targeting strategy for treatment of glioma Journal of Neurosurgery. 104: 583-592. PMID 16619663 DOI: 10.3171/Jns.2006.104.4.583 |
0.436 |
|
| 2006 |
Velicu S, Han Y, Ulasov I, Brown IE, Andaloussi AE, Gajewski TF, Lesniak MS. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy Journal of Neuroimmunology. 174: 74-81. PMID 16504307 DOI: 10.1016/J.Jneuroim.2006.01.016 |
0.429 |
|
| 2006 |
Lesniak MS. Targeted therapy for malignant glioma: Neural stem cells Expert Review of Neurotherapeutics. 6: 1-3. PMID 16466305 DOI: 10.1586/14737175.6.1.1 |
0.396 |
|
| 2006 |
Sonabend AM, Ulasov IV, Lesniak MS. Conditionally replicative adenoviral vectors for malignant glioma Reviews in Medical Virology. 16: 99-115. PMID 16416455 DOI: 10.1002/Rmv.490 |
0.377 |
|
| 2006 |
Lesniak MS. Contemporary management of pituitary tumors Expert Review of Anticancer Therapy. 6: S1-S2. DOI: 10.1586/14737140.6.9S.S1 |
0.313 |
|
| 2006 |
Lesniak M, Ulasov I, Zhu Z, Curiel D. Transductional and transcriptional targeting enhances adenoviral virotherapy of malignant glioma Journal of the American College of Surgeons. 203: S38. DOI: 10.1016/J.Jamcollsurg.2006.05.086 |
0.312 |
|
| 2005 |
Lesniak MS, Kelleher E, Pardoll D, Cui Y. Targeted gene therapy to antigen-presenting cells in the central nervous system using hematopoietic stem cells. Neurological Research. 27: 820-6. PMID 16354542 DOI: 10.1179/016164105X49454 |
0.381 |
|
| 2005 |
Hsieh JC, Lesniak MS. Surgical management of high-grade gliomas Expert Review of Neurotherapeutics. 5: S33-S39. PMID 16274269 DOI: 10.1586/14737175.5.6.S33 |
0.385 |
|
| 2005 |
Sonabend AM, Lesniak MS. Oligodendrogliomas: Clinical significance of 1p and 19q chromosomal deletions Expert Review of Neurotherapeutics. 5: S25-S32. PMID 16274268 DOI: 10.1586/14737175.5.6.S25 |
0.323 |
|
| 2005 |
Lesniak MS. Brain tumors: Controversies and challenges in management Expert Review of Neurotherapeutics. 5: S1-S2. PMID 16274264 DOI: 10.1586/14737175.5.6.S1 |
0.36 |
|
| 2005 |
Sikorski CW, Lesniak MS. Immunotherapy for malignant glioma: Current approaches and future directions Neurological Research. 27: 703-716. PMID 16197807 DOI: 10.1179/016164105X49481 |
0.375 |
|
| 2005 |
Hsu W, Lesniak MS, Tyler B, Brem H. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma. Journal of Neuro-Oncology. 74: 135-40. PMID 16193383 DOI: 10.1007/S11060-004-6597-8 |
0.352 |
|
| 2005 |
Lesniak MS. Novel advances in drug delivery to brain cancer Technology in Cancer Research and Treatment. 4: 417-428. PMID 16029060 DOI: 10.1177/153303460500400409 |
0.407 |
|
| 2005 |
Ferguson S, Lesniak MS. Percival Bailey and the classification of brain tumors Neurosurgical Focus. 18: e7. PMID 15844870 DOI: 10.3171/Foc.2005.18.4.8 |
0.371 |
|
| 2005 |
Zhu ZB, Houdt WJ, Haviv YS, Lu B, Wang M, Rivera AA, Ulasov IV, Lesniak MS, Siegal GP, Dirven CMF, Curiel DT. 537. Transcriptionally Targeting the Survivin Promoter to Human Gliomas Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.077 |
0.468 |
|
| 2004 |
Lesniak MS, Gabikian P, Tyler BM, Pardoll DM, Brem H. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. Journal of Neuro-Oncology. 70: 23-8. PMID 15527103 DOI: 10.1023/B:Neon.0000040821.50347.C5 |
0.386 |
|
| 2004 |
Lesniak MS, Brem H. Targeted therapy for brain tumours Nature Reviews Drug Discovery. 3: 499-508. PMID 15173839 DOI: 10.1038/Nrd1414 |
0.352 |
|
| 2003 |
Lesniak MS, Tyler BM, Pardoll DM, Brem H. Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2. Journal of Neuro-Oncology. 64: 155-60. PMID 12952296 DOI: 10.1007/BF02700030 |
0.461 |
|
| 2001 |
Lesniak MS, Langer R, Brem H. Drug delivery to tumors of the central nervous system Current Neurology and Neuroscience Reports. 1: 210-216. PMID 11898520 DOI: 10.1007/S11910-001-0020-Z |
0.37 |
|
| 2000 |
Lesniak MS, Sampath P, DiMeco F, Viglione MP, Tyler BM, Pardoll DM, Brem H. Comparative analysis of paracrine immunotherapy in experimental brain tumors. Neurosurgical Focus. 9: e4. PMID 16817687 DOI: 10.3171/Foc.2000.9.6.5 |
0.394 |
|
| Show low-probability matches. |